Lilly’s antibody for COVID-19 protection starts nursing home trial
pharmaphorum
AUGUST 3, 2020
The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian biotech AbCellera – in a phase 3 trial to see if it can prevent the spread of the coronavirus among residents and staff in US nursing homes.
Let's personalize your content